La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Is minocycline useful for therapy of acute viral encephalitis?

Identifieur interne : 001196 ( Main/Exploration ); précédent : 001195; suivant : 001197

Is minocycline useful for therapy of acute viral encephalitis?

Auteurs : Alan C. Jackson [Canada]

Source :

RBID : pubmed:22728256

English descriptors

Abstract

Minocyline is a tetracycline derivative with anti-inflammatory, anti-apoptotic, and anti-oxidant properties. Therapy has proved useful in some experimental models of both noninfectious and infectious neurological diseases and also in clinical trials in humans, including acute traumatic cervical spinal cord injury. In models of viral encephalitis, treatment has shown both beneficial and deleterious effects. In reovirus infection in mice, minocycline delayed the disease, but did not improve either the morbidity or mortality of the disease. In neuroadapted Sindbis virus infection of mice, minocycline prevented disease, but therapy needed to be given before clinical signs were present in most of the animals. In experimental rabies in neonatal mice minocycline aggravated the disease, likely related to anti-inflammatory effects. Minocycline has also been shown to aggravate disease in a mouse model of Huntington disease, in a monkey model of Parkinson disease, and in a mouse model of hypoxic-ischemic brain injury. Hence, there is experimental evidence of benefit of minocycline in both infectious and noninfectious neurological diseases, but there is a lack of benefit and harmful effects in other diseases. This may reflect multiple mechanisms of actions that cannot be predicted in a new disease or in an infection caused by a specific viral agent. Minocycline therapy is a double-edged sword and this drug should not be given empirically to patients with acute viral encephalitis for anticipated neuroprotective effects. Much more work needs to be done in experimental models in animals as well as in clinical trials. Because patient enrollment in clinical trials on acute viral encephalitis has proven to be difficult, funding will be a challenge.

DOI: 10.1016/j.antiviral.2012.06.005
PubMed: 22728256


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Is minocycline useful for therapy of acute viral encephalitis?</title>
<author>
<name sortKey="Jackson, Alan C" sort="Jackson, Alan C" uniqKey="Jackson A" first="Alan C" last="Jackson">Alan C. Jackson</name>
<affiliation wicri:level="4">
<nlm:affiliation>Departments of Internal Medicine (Neurology) and of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada. ajackson2@hsc.mb.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Departments of Internal Medicine (Neurology) and of Medical Microbiology, University of Manitoba, Winnipeg, MB</wicri:regionArea>
<orgName type="university">Université du Manitoba</orgName>
<placeName>
<settlement type="city">Winnipeg</settlement>
<region type="state">Manitoba</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22728256</idno>
<idno type="pmid">22728256</idno>
<idno type="doi">10.1016/j.antiviral.2012.06.005</idno>
<idno type="wicri:Area/PubMed/Corpus">000A27</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A27</idno>
<idno type="wicri:Area/PubMed/Curation">000A27</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A27</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000A27</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A27</idno>
<idno type="wicri:Area/Ncbi/Merge">001178</idno>
<idno type="wicri:Area/Ncbi/Curation">001178</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001178</idno>
<idno type="wicri:Area/Main/Merge">001220</idno>
<idno type="wicri:Area/Main/Curation">001196</idno>
<idno type="wicri:Area/Main/Exploration">001196</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Is minocycline useful for therapy of acute viral encephalitis?</title>
<author>
<name sortKey="Jackson, Alan C" sort="Jackson, Alan C" uniqKey="Jackson A" first="Alan C" last="Jackson">Alan C. Jackson</name>
<affiliation wicri:level="4">
<nlm:affiliation>Departments of Internal Medicine (Neurology) and of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada. ajackson2@hsc.mb.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Departments of Internal Medicine (Neurology) and of Medical Microbiology, University of Manitoba, Winnipeg, MB</wicri:regionArea>
<orgName type="university">Université du Manitoba</orgName>
<placeName>
<settlement type="city">Winnipeg</settlement>
<region type="state">Manitoba</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j">Antiviral research</title>
<idno type="eISSN">1872-9096</idno>
<imprint>
<date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Anti-Inflammatory Agents (administration & dosage)</term>
<term>Anti-Inflammatory Agents (adverse effects)</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Encephalitis, Viral (drug therapy)</term>
<term>Encephalomyelitis (drug therapy)</term>
<term>Mice</term>
<term>Minocycline (administration & dosage)</term>
<term>Minocycline (adverse effects)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Anti-Inflammatory Agents</term>
<term>Minocycline</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en">
<term>Anti-Inflammatory Agents</term>
<term>Minocycline</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Encephalitis, Viral</term>
<term>Encephalomyelitis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Drug-Related Side Effects and Adverse Reactions</term>
<term>Mice</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Minocyline is a tetracycline derivative with anti-inflammatory, anti-apoptotic, and anti-oxidant properties. Therapy has proved useful in some experimental models of both noninfectious and infectious neurological diseases and also in clinical trials in humans, including acute traumatic cervical spinal cord injury. In models of viral encephalitis, treatment has shown both beneficial and deleterious effects. In reovirus infection in mice, minocycline delayed the disease, but did not improve either the morbidity or mortality of the disease. In neuroadapted Sindbis virus infection of mice, minocycline prevented disease, but therapy needed to be given before clinical signs were present in most of the animals. In experimental rabies in neonatal mice minocycline aggravated the disease, likely related to anti-inflammatory effects. Minocycline has also been shown to aggravate disease in a mouse model of Huntington disease, in a monkey model of Parkinson disease, and in a mouse model of hypoxic-ischemic brain injury. Hence, there is experimental evidence of benefit of minocycline in both infectious and noninfectious neurological diseases, but there is a lack of benefit and harmful effects in other diseases. This may reflect multiple mechanisms of actions that cannot be predicted in a new disease or in an infection caused by a specific viral agent. Minocycline therapy is a double-edged sword and this drug should not be given empirically to patients with acute viral encephalitis for anticipated neuroprotective effects. Much more work needs to be done in experimental models in animals as well as in clinical trials. Because patient enrollment in clinical trials on acute viral encephalitis has proven to be difficult, funding will be a challenge.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
<region>
<li>Manitoba</li>
</region>
<settlement>
<li>Winnipeg</li>
</settlement>
<orgName>
<li>Université du Manitoba</li>
</orgName>
</list>
<tree>
<country name="Canada">
<region name="Manitoba">
<name sortKey="Jackson, Alan C" sort="Jackson, Alan C" uniqKey="Jackson A" first="Alan C" last="Jackson">Alan C. Jackson</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001196 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001196 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:22728256
   |texte=   Is minocycline useful for therapy of acute viral encephalitis?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22728256" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1 

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022